ACT vs REGN · P/E 9.3, rev $1.20B vs P/E 14, rev $14.34B
Enact Holdings Inc (ACT) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Enact Holdings Inc (ACT) is a insurance - specialty company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported ACT revenue for 2024-12-31 was $1.20B. Revenue was up 4.2% from 2023-12-31 to 2024-12-31. ACT currently screens at market cap $5.99B and trailing P/E 9.3.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
ACT currently screens at market cap $5.99B and trailing P/E 9.3. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the ACT and REGN stock pages for the full models.
Not investment advice.